INTRODUCTION

The World Health Organization recommendation is that all 36.7 million people living with human immunodeficiency virus (HIV) (67% in Sub-Saharan Africa) are eligible for antiretrovirals (ARV) drugs. There is still a controversy over how frequently lipodystrophy occurs, especially with the presumption that the prevalence of lipodystrophy syndrome, in the form of lipohypertrophy and lipoatrophy, is still prevalent. Lipodystrophy is associated with disorders in lipid metabolism such as elevated serum concentrations of total cholesterol, triglycerides, low-density lipoproteins (LDL), and very low levels of high-density lipoproteins (HDL).

The consequences of lipodystrophy syndrome are both psychosocial and medical. There is also an association with the duration of treatment, and certain drugs have irreversible side effects. Therefore, lipodystrophy syndrome, in the form of lipohypertrophy and lipoatrophy, is still prevalent. Lipodystrophy is associated with disorders in lipid metabolism such as elevated serum concentrations of total cholesterol, triglycerides, low-density lipoproteins (LDL), and very low levels of high-density lipoproteins (HDL).

The aim of this study was to determine the role of surgical intervention in the medical (change in serum lipogram levels), physical, and psychosocial management of ARV-associated lipodystrophy.
PATIENTS AND METHODS
This prospective clinical trial was conducted at Chris Hani Baragwaneth Academic Hospital in Soweto, South Africa. Sixty-one consecutive patients with ARV-associated lipodystrophy had a surgical intervention in the form of lipoectomy or liposuction. Nine patients were lost to follow-up; therefore, 52 patients were included in the study. One patient underwent both a bilateral breast reduction (BBR) and liposuction for buffalo hump, and therefore the total data are for 53 surgical procedures.

Patients were referred from HIV specialist centers. The diagnosis of lipohypertrophy is based on clinical assessment. The inclusion criteria are: HIV positive on ARVs, referred with ARV-induced lipodystrophy syndrome, had at least one change by an HIV specialist in their ARV regime, the lipodystrophy was stable for at least 1 year, over the age of 18 years, surgically fit, and gave informed consent as laid out by ethics committee at the University of Witwatersrand, under their approval.

The primary end point of surgical correction was medical risk reduction measured by serum fasting lipograms (total cholesterol, triglyceride, and LDL and HDL cholesterol) taken 24–48 hours preoperatively and a repeat fasting lipogram 9–12 months postoperatively. The normal ranges are defined as total cholesterol <5 mmol/L, triglycerides <1.7 mmol/L, LDL cholesterol <3 mmol/L, and HDL cholesterol ≥1.2 mmol/L. No specific dietary or lifestyle advice was given, and patients returned to their preoperative lifestyle and activity level 1 month after surgical correction. A subcohort of 35 patients who had deranged preoperative lipograms was analyzed in the same way.

The secondary end points of this study include: the impact of surgical intervention on the patients, postoperative complications, and recurrence rates. This was done via patient feedback, clinical examination, and measurements. These were done preoperatively, 1, 3, and 9–12 months postoperatively.

RESULTS
The mean age is 26 years (range 22–54), and 51 of the 52 patients (98.1%) are women.

Fifty-two patients had 53 surgical procedures. In total, 23 patients with macromastia had BBR, 11 patients with increased abdominal pannus had abdominoplasty, and 19 patients had liposuction for their dorsal humps. Overall, there is no statistically significant difference in any of the preoperative and postoperative lipogram values, as summarized in Table 1.

Of the 52 patients, 35 had some form of derangement on their preoperative fasting lipograms. Twenty-four patients had raised total cholesterol, 18 raised triglycerides, 21 raised LDL cholesterol, and 4 lowered HDL cholesterol values. The patient who had both a BBR and liposuction had a normal preoperative fasting lipogram.

The subgroup of patients with one or more deranged value on their preoperative fasting lipogram show a statistically significant (P < 0.05) decrease in their postoperative cholesterol (P = 0.001), triglycerides (P = 0.004), and LDL cholesterol (P = 0.017). There was no statistically significant change in the HDL cholesterol (P = 0.066). Most clinically significant in terms of risk factors are the triglycerides. Figure 1 shows, in the subgroup with elevated/abnormal preoperative triglycerides, the statistically significant (P < 0.004) effect of surgical intervention on triglyceride levels postoperatively. The median preoperative and postoperative cholesterol, triglyceride, and LDL and HDL cholesterol in this subgroup are indicated in Table 2.

Three patients presented with recurrence, 1 patient with post BBR at 12 months (this patient has a reoperative procedure that did not form part of this trial), and 2 patients with dorsal humps had recurrences at 9 and 11 months, respectively.

The median resection mass of all surgical corrective procedures was 1,150g. There was no statistically significant difference between resection mass and changes in lipogram values (P = 0.965). The median resection volume postliposuction for dorsal hump was 650mL. In this group, there was also no statistically significant difference (P = 0.84) between resection volume and alteration in lipogram values.

No major complications were reported. The minor complications in each group are seen in Table 3. All complications were treated conservatively and did not require hospital admission or subsequent surgical management or intervention.

DISCUSSION
The prevalence of lipodystrophy in South Africa is reported as 11.7% in a random clinical cohort study of 497 patients. Significantly, 5.9% of these patients reported that they would stop taking ARVs based on this side effect alone, which influences their morbidity and mortality and poses a potential public health risk with regard to resistance. Lipodystrophy is common in a resource-limited setting, and has implications for risk of metabolic disease; quality of life, adherence, and comprehensive evidence-based interventions are required.

| Table 1. Data for All Patients |
|-----------------------------|
| Preoperative Median Value (mmol/L) | Postoperative Median Value (mmol/L) | P | Normal Range (mmol/L) |
| Total cholesterol | 4.938 | 4.938 | 0.379 | <5 |
| Triglycerides | 1.594 | 1.506 | 0.965 | <1.7 |
| HDL cholesterol | 1.310 | 1.312 | 0.168 | >1.2 |
| LDL cholesterol | 2.839 | 2.698 | 0.137 | <3 |
Triglyceride levels of 150 mg/dl or 1.7 mmol/L or more constitute a risk factor for metabolic syndrome, coronary artery disease, stroke, and type 2 diabetes mellitus and peripheral vascular disease. Triglyceride levels are dose-dependently associated with a greater risk of cardiovascular disease, and they all affect mortality. The incidence of coronary artery disease increases by 20% with an increase of triglycerides of 0.2 mmol/L. In our study, in the subgroup of patients with deranged preoperative triglyceride levels, their triglyceride level decreased by an average of 1.44 mmol/L in the postoperative follow-up ($P = 0.004$), which can be equated to a 120% risk reduction.

Evidence of a graded and strong correlation between total blood cholesterol and LDL cholesterol and risk for cardiovascular disease has been shown, and these are considered independent risk factors. Meta-analyses of multiple statin trials demonstrate that for every 1.0 mmol/L reduction in LDL cholesterol, there is an associated 20%–25% decrease in cardiovascular mortality and nonfatal myocardial infarctions. In our study, there was a statistically significant decrease in the total cholesterol ($P = 0.004$) and the LDL cholesterol ($P = 0.017$) in the subset of high-risk patients that had deranged preoperative lipogram values. The median LDL cholesterol levels pre and postoperatively were 3.6 and 3.2 mmol/L, respectively, which equates to an 8%–10% decrease in cardiovascular mortality and nonfatal myocardial infarctions.

Although most evidence is based on the general population, there is some evidence and confounding factors specific to HIV- and ARV-induced lipodystrophy. Cardiovascular disease risk factors are elevated in HIV-positive patients with fat redistribution. There is a strong association between lipohypertrophy and coronary artery calcium scores and the progression of subclinical atherosclerosis. A meta-analysis by Viganò et al found that the incidence of associated new-onset hypercholesterolemia and hypertriglyceridemia is 24% and 19%, respectively, in lipodystrophy syndrome.

In the general population, Swanson reported preoperative high triglycerides in 36.8% of patients who underwent liposuction. Similarly, in our study among the population of ARVs, 34% of the patients had high preoperative triglyceride levels. Earlier studies, prior to the prospective clinical study by Swanson that look at changes in lipid levels associated with lumpectomy and liposuction, have shown incongruent results and are mostly small groups (9–15 patients), which limit its statistical significance, and are predominantly in obese female patients. All studies were conducted on the general population and none exclusively on HIV-positive patients with ARV-associated lipodystrophy syndrome.

In a study by Ybarra et al., a reduction in triglyceride levels and an increase in cholesterol levels were seen 4 months after abdominal liposuction. However, Robles-Cervantes et al. found that 1 month after abdominal liposuction there was no significant changes in lipid values. A large prospective study on 322 patients conducted by Swanson showed a significant ($P < 0.001$)
reduction in triglyceride levels although the cholesterol levels remained unchanged in patients with elevated preoperative levels of triglycerides postliposuction and liposuction/abdominoplasty. The results from our study show that in the subgroup of patients with elevated preoperative triglyceride levels, there is a statically significant decrease in triglyceride levels postoperatively ($P = 0.004$) as well as cholesterol ($P = 0.001$) and LDL cholesterol ($P = 0.017$).

Danilla et al\textsuperscript{22} report, in a meta-analysis, that there is a statistically significant difference when comparing patients by treatment areas, and hence suggested that the overall volume of subcutaneous fat removed is relevant as opposed to anatomical location. Swanson\textsuperscript{22} found that liposuction patients who had aspirate volumes of at least 3,000 ml had a greater reduction in triglyceride levels than those with lower aspirate volumes. Our study however had a median resection volume of 1,150 ml less than half that reported by Swanson.\textsuperscript{22} No statistically significant difference between resection volumes and changes in lipogram values ($P = 0.965$) was found. Nor did the subgroup of patients with elevated triglyceride levels preoperatively show a statistically significant difference in the resection volumes and response to treatment ($P = 0.685$). Perhaps this is due to altered pathophysiology associated with lipodystrophy syndrome as opposed to the general population represented by studies conducted to date.

Potential limitations of this study are that it was conducted a few years ago when a large number of older ARV agents were routinely used, and that follow-up serology and blood tests were done 9–12 months later, which is a longer follow-up time than that reported for most of the other studies, as resource constraints on laboratory services exist.

**CONCLUSIONS**

No previous studies, to the researcher’s knowledge, have reviewed the effect of lipoctomy/liposuction in HIV-positive patients with ARV-induced lipodystrophy syndrome on lipid profiles pre-and postoperatively. There was a statistically significant decrease in triglyceride, total cholesterol, and LDL cholesterol levels postoperatively in patients with elevated preoperative levels. The potential impact of this is multifactorial and could not only change the cardiovascular risk profiles of patients, affect morbidity and mortality, as well as quality of life and the burden of disease, but also provide an effective standard of treatment in the future.

**Sheree Debbie Koonin, MBBCCh (Wits)**
Department Plastic and Reconstructive Surgery
University of Witwatersrand
P O Box 26, Wendwood
Sandton 2144, South Africa
E-mail: shereekoonin@gmail.com

**ACKNOWLEDGMENT**

*Human Research Ethics Committee (Medical) University of Witwatersrand approval number: M150768.*

**REFERENCES**

1. World Health Organization. HIV/AIDS. Updated July 6, 2020. Available at: http://www.who.int/en/news-room/factsheets/detail/hiv-aids. Accessed October 29, 2017.
2. Gelpa M, Afzal S, Fuchs A, et al. Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors. AIDS. 2019;33:675–683.
3. Alkhani A, Morin H, Matte S, et al. Association between lipodystrophy and length of exposure to ARIs in adult HIV-1 infected patients in Montreal. BMJ Infect Dis. 2019;19:820.
4. Wohl DA, McConsey G, Tebas P, et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis. 2006;43:645–653.
5. Carr A, Emery S, Law M, et al; HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361:726–735.
6. Sprinz E, Lazzaretti RK, Kuhmmer R, et al. Dyslipidemia in HIV-infected individuals. Braz J Infect Dis. 2010;14:575–588.
7. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48–62.
8. Troll JG. Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection. Curr Atheroscler Rep. 2011;13:51–56.
9. Boccafa F. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. AIDS. 2008;22(suppl 3):S19–S26.
10. Zinn RJ, Serrurier C, Takuya S, et al. HIV-associated lipodystrophy in South Africa: the impact on the patient and the impact on the plastic surgeon. J Plast Reconstr Aesthet Surg. 2013;66:839–844.
11. Finkelstein JL, Gala P, Rochford R, et al. HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settings. J Int AIDS Soc. 2015;18:19033.
12. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607.
13. Liese AD, Mayer-Davis EJ, Haffner SM. Development of the multiple metabolic syndrome: an epidemiologic perspective. Epidemiol Rev. 1998;20:157–172.
14. American Heart Association. About Metabolic Syndrome. Updated:Oct 20, 2017. Available at: http://www.heart.org/HEARTORG/Conditions/More About Metabolic Syndrome/About-Metabolic-Syndrome_UCM_301920_Article.jsp. Accessed November 9, 2017.
15. Liu E, Armstrong C, Spiegelman D, et al. First-line antiretroviral therapy and changes in lipid levels over 3 years among HIV-infected adults in Tanzania. Clin Infect Dis. 2013;56:1820–1828.
16. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 individuals in 52 cohorts. Circulation. 2007;115:450–458.
17. Graham I, Cooney MT, Bradley D, et al. Dyslipidemias in the prevention of cardiovascular disease: risks and causality. Curr Cardiol Rep. 2012;14:709–720.
18. Mihaylova B, Emberson J, Blackwell L, et al; Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–590.
19. Cerrato E, Calcagno A, D’Ascenzo F, et al. Cardiovascular disease in HIV patients: from bench to bedside and backwards. Open Heart. 2015;2:e000174.
20. Gualraldi G, Stentarelli C, Zona S, et al. HIV-associated lipodystrophy: impact of antiretroviral therapy. Drugs. 2013;73:1431–1450.
21. Viganò A, Brambilla P, Cafarelli L, et al. Normalization of fat accrual in lipatrophy, HIV-infected children switched from
stavudine to tenofovir and from protease inhibitor to efavirenz. *Antivir Ther.* 2007;12:297–302.

22. Swanson E. Prospective clinical study reveals significant reduction in triglyceride level and white blood cell count after liposuction and abdominoplasty and no change in cholesterol levels. *Plast Reconstr Surg.* 2011;128:182c–197c.

23. Samdal F, Birkeland KI, Ose L, et al. Effect of large-volume liposuction on sex hormones and glucose- and lipid metabolism in females. *Aesthetic Plast Surg.* 1995;19:131–135.

24. Baxter RA. Serum lipid changes following large-volume suction lipectomy. *Aesthet Surg J.* 1997;17:213–215.

25. González-Ortiz M, Robles-Cervantes JA, Cárdenas-Camarena L, et al. The effects of surgically removing subcutaneous fat on the metabolic profile and insulin sensitivity in obese women after large-volume liposuction treatment. *Horm Metab Res.* 2002;34:446–449.

26. Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. *N Engl J Med.* 2004;350:2549–2557.

27. Giese SY, Buhaj EJ, Commons GW, et al. Improvements in cardiovascular risk profile with large-volume liposuction: a pilot study. *Plast Reconstr Surg.* 2001;108:510–519.

28. Ybarra J, Blanco-Vaca F, Fernández S, et al. The effects of liposuction removal of subcutaneous abdominal fat on lipid metabolism are independent of insulin sensitivity in normal-overweight individuals. *Obes Surg.* 2008;18:408–414.

29. Robles-Cervantes JA, Castillo-Salcedo T, Guerrerossantos J, et al. Behavior of visfatin in nonobese women undergoing liposuction: a pilot study. *Aesthet Surg J.* 2010;30:730–732.

30. Danilla S, Longton C, Valenzuela K, et al. Suction-assisted lipectomy fails to improve cardiovascular metabolic markers of disease: a meta-analysis. *J Plast Reconstr Aesthet Surg.* 2013;66:1557–1563.